Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B Clinical Trial

Official title:

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01248884
• Other study ID #: 113948
• Status: Completed
• Phase: Phase 2
• Start date: December 9, 2010
• Est. completion date: January 5, 2012

Study information

• Verified date: July 2014
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4 months of age.

Description:

This Protocol Posting has been updated following Protocol Amendment 1, February 2011, leading to the update of the exclusion criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 721
• Est. completion date: January 5, 2012
• Est. primary completion date: January 5, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Days to 90 Days

Eligibility

Inclusion Criteria:

• A male or female between, and including, 60 and 90 days of age at the time of the first vaccination.

• Born after a gestation period of 37 to 42 weeks inclusive.

• Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.

• Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Child in care.

• Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs since birth.

• Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, or planned administration during the study period, with the exception of oral rotavirus vaccination which is allowed at any time during the study.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

• Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, Hib and/or pneumococcal vaccination or disease, with the exception of hepatitis B vaccination at birth.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• Family history of congenital or hereditary immunodeficiency.

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).

• Major congenital defects or serious chronic illness.

• History of any neurological disorders or seizures.

• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

• Acute disease and/or fever at the time of enrolment.

Related Conditions & MeSH terms

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type b
• Hepatitis B
• Poliomyelitis
• Tetanus

Intervention

Biological:
• Infanrix hexa™
3 doses, intramuscular into left thigh
• Prevenar 13®
3 co-administered doses, intramuscular into right thigh
• GSK217744
3 doses, intramuscular into left thigh

Locations

Country	Name	City	State
Dominican Republic	GSK Investigational Site	Santo Domingo
Dominican Republic	GSK Investigational Site	Santo Domingo, Distrito Nacional
Finland	GSK Investigational Site	Espoo
Finland	GSK Investigational Site	Helsinki
Finland	GSK Investigational Site	Helsinki
Finland	GSK Investigational Site	Jarvenpaa
Finland	GSK Investigational Site	Kokkola
Finland	GSK Investigational Site	Kuopio
Finland	GSK Investigational Site	Lahti
Finland	GSK Investigational Site	Oulu
Finland	GSK Investigational Site	Pori
Finland	GSK Investigational Site	Seinajoki
Finland	GSK Investigational Site	Tampere
Finland	GSK Investigational Site	Turku
Finland	GSK Investigational Site	Vantaa
Finland	GSK Investigational Site	Vantaa

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Dominican Republic,  Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations = 0.1 international units per milliliter (IU/mL).	At Month 0
Primary	Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.	A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations = 0.1 international units per milliliter (IU/mL).	At Month 3
Primary	Concentrations for Anti-pertussis Toxoid (Anti-PT) and Anti-pertactin (Anti-PRN) Antibodies.	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was = 5 enzyme-linked immunosorbent assay (ELISA) units per milliliters (EL.U/mL).	At Month 0
Primary	Concentrations for Anti-pertussis Toxoid (Anti-PT) and Anti-pertactin (Anti-PRN) Antibodies.	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was = 5 enzyme-linked immunosorbent assay (ELISA) units per milliliters (EL.U/mL).	At Month 3
Primary	Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.	A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations = 0.15 micrograms per milliliter (µg/mL).	At Month 3
Primary	Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (=) 10 and 100 Milli-International Units Per Milliliter (mIU/mL)	A seroprotected subject was defined as a vaccinated subject who had anti-HBs antibody concentrations = 10 mIU/mL. A decrease in the specificity of the anti-HB enzyme-linked immunosorbent assay (ELISA) had been observed in some studies for low levels of antibody (10-100 mIU/mL). All the available blood samples initially tested with ELISA were re-tested using the Chemi Luminescence Immuno Assay (CLIA) approved by the US Food and Drug Administration (FDA). The table shows updated results following partial or complete retesting/reanalysis.	At Month 3
Primary	Concentrations for Anti-HBs Antibodies = 10 and 100 mIU/mL	A decrease in the specificity of the anti-HB enzyme-linked immunosorbent assay (ELISA) had been observed in some studies for low levels of antibody (10-100 mIU/mL). All the available blood samples initially tested with ELISA were re-tested using the Chemi Luminescence Immuno Assay (CLIA) approved by the US Food and Drug Administration (FDA). The table shows updated results following partial or complete retesting/reanalysis. Concentrations were expressed as geometric mean concentrations (GMCs) in milli-International units per milliliter (mIU/mL).	At Month 3
Secondary	Concentrations for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.	At Months 0 and 3
Secondary	Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT) and Anti-pertactin (Anti-PRN) Antibodies.	A seropositive subject was defined as a vaccinated subject who had anti-PT and anti-PRN antibody concentrations = 5 EL.U/mL.	At Months 0 and 3
Secondary	Concentrations for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.	Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was = 0.15 µg/mL.	At Month 3
Secondary	Number of Seropositive Subjects for Anti-pneumococcal (Anti-PNE) Serotypes.	A seropositive subject was defined as a vaccinated subject who had anti- pneumococcal antibody concentrations = 0.15 micrograms per milliliter (µg/mL). The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.	At Month 3
Secondary	Concentrations for Anti-PNE Antibodies.	Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 0.15 µg /mL. The anti-PNE serotypes assessed were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.	At Month 3
Secondary	Number of Subjects With a Vaccine Response to PT and PRN.	Vaccine response defined as: for initially seronegative subjects, antibody concentration = 5 EL.U/mL at 1 month post primary vaccination (Month 3); for initially seropositive subjects, antibody concentration at 1 month post primary vaccination (Month 3) = 1 fold the pre-vaccination antibody concentration.	At Month 3
Secondary	Number of Subjects Reporting Any Solicited Local Symptoms.	Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade.	During the 8-day (Days 0-7)
Secondary	Number of Subjects Reporting Any Solicited General Symptoms.	Solicited local symptoms assessed were drowsiness, irritability, loss of appetite and fever [axillary temperature above (=) 37.5 degrees Celsius (°C)]. Any = occurrence of any local symptom regardless of intensity grade.	During the 8-day (Days 0-7)
Secondary	Number of Subjects Reporting Any Unsolicited Adverse Events (AEs).	An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination.	Within the 31-day (Days 0-30) follow up period after vaccination.
Secondary	Number of Subjects Reporting Any Serious Adverse Events (SAEs).	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Any SAE = any SAE regardless of assessment of relationship to study vaccination.	During the entire study period (Month 0 to Month 3)